The diagnostic value of serum DSA-TRF in hepatocellular carcinoma
TRF is a glycoprotein mainly secreted by hepatocytes, The aim of this study was to explore the diagnostic value of aberrant glycosylated serum transferrin (TRF) especially containing multi-antennary glycans in hepatocellular carcinoma (HCC).A total of 581 subjects including HCC patients, liver cirrhosis (LC) patients, chronic hepatitis (CHB) patients and healthy controls (HC) were recruited. All the subjects were randomly assigned to training group (n = 411) and validation group (n = 170). We firstly analyzed the serum protein N-glycome profiling of HCC, LC, and HC by DNA sequencer–assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) technology. We established a lectin-antibody sandwich ELISA (Lectin-ELISA) method to detect multi-antennary glycans-contained TRF (DSA-TRF) in serum, in which Datura stramonium Agglutinin (DSA) was used for specific recognition. Levels of serum DSA-TRF and TRF were analyzed respectively. The diagnostic efficacies of DSA-TRF and TRF of differentiating HCC patients from CHB, LC patients and HC within the training group were evaluated using receiver operating characteristic (ROC) curve and tested in the validation group.The result found that in training group, serum TRF and DSA-TRF levels differed significantly between HCC (1.86 ± 0.50, g/L, 0.285 ± 0.06), CHB + LC (2.39 ± 0.74, g/L, 0.189 ± 0.07) and HC (1.92 ± 0.69, g/L, 0.249 ± 0.09) (HCC vs. CHB + LC, P < 0.001; HCC vs. HC, P < 0.001; CHB + LC vs. HC, P < 0.001). The area under the ROC curve (AUC) of DSA-TRF was significantly superior to AFP (0.880, 95%CI: 0.834–0.925 vs. 0.776, 95%CI: 0.725–0.827, P = 0.003) in differentiating HCC from CHB + LC. The AUC of diagnostic model GlycoTRF1 (0.981, 95%CI: 0.969–0.993) was higher than DSA-TRF and AFP alone (P<0.001) in differentiating HCC from CHB + LC, which was verified in validation group.The results indicated that the serum DSA-TRF might serve as a potential glycan biomarker for distinguishing HCC from CHB and LC.
KeywordsTransferrin Hepatocellular carcinoma Glycan biomarker
This study was funded by the National Science and Technology Major Project of China (2018ZX10302205-003) and the Science and Technology Commission of Shanghai Municipality(17JC1404500, 17411960500, 15JC1404100).
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 6.Ko, Y.S., Bae, J.H., Sinn, D.H., Gwak, G.Y., Kang, W., Paik, Y.H., Choi, M.S., Lee, J.H., Koh, K.C., Paik, S.W.: The Clinical Significance of Serum Alpha-fetoprotein in Diagnosing Hepatocellular Carcinoma in a Health Screening Population. Korean J Gastroenterol. 69(4), 232–238 (2017)CrossRefGoogle Scholar
- 9.Leerapun, A., Suravarapu, S.V., Bida, J.P., Clark, R.J., Sanders, E.L., Mettler, T.A., Stadheim, L.M., Aderca, I., Moser, C.D., Nagorney, D.M., LaRusso, N.F., de Groen, P.C., Menon, K.V., Lazaridis, K.N., Gores, G.J., Charlton, M.R., Roberts, R.O., Therneau, T.M., Katzmann, J.A., Roberts, L.R.: The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin. Gastroenterol. Hepatol. 5(3), 394–402, 267 (2007)CrossRefGoogle Scholar
- 12.Comunale, M.A., Wang, M., Anbarasan, N., Betesh, L., Karabudak, A., Moritz, E., Devarajan, K., Marrero, J., Block, T.M., Mehta, A.: Total serum glycan analysis is superior to lectin-FLISA for the early detection of hepatocellular carcinoma. Proteomics Clin. Appl. 7(9–10), 690–700 (2013)PubMedPubMedCentralGoogle Scholar
- 13.Comunale, M.A., Lowman, M., Long, R.E., Krakover, J., Philip, R., Seeholzer, S., Evans, A.A., Hann, H.W., Block, T.M., Mehta, A.S.: Proteomic analysis of serum associated fucosylated glycoproteins in the development of primary hepatocellular carcinoma. J. Proteome Res. 5(2), 308–315 (2006)CrossRefGoogle Scholar
- 14.Miyahara, K., Nouso, K., Dohi, C., Morimoto, Y., Kinugasa, H., Wada, N., Takeuchi, Y., Kuwaki, K., Onishi, H., Ikeda, F., Miyake, Y., Nakamura, S., Shiraha, H., Takaki, A., Amano, M., Nishimura, S.I., Yamamoto, K.: Alteration of N-glycan profiles in patients with chronic hepatitis and hepatocellular carcinoma. Hepatol. Res. 45(9), 986–993 (2015)CrossRefGoogle Scholar
- 19.Liu, X.E., Desmyter, L., Gao, C.F., Laroy, W., Dewaele, S., Vanhooren, V., Wang, L., Zhuang, H., Callewaert, N., Libert, C., Contreras, R., Chen, C.: N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology. 46(5), 1426–1435 (2007)CrossRefGoogle Scholar
- 27.Shimomura, M., Nakayama, K., Azuma, K., Terao, N., Nishino, K., Takamatsu, S., Nakano, M., Takahashi, S., Kobayashi, Y., Murata, K., Kamada, Y., Miyoshi, E.: Establishment of a novel lectin-antibody ELISA system to determine core-fucosylated haptoglobin. Clin. Chim. Acta. 446, 30–36 (2015)CrossRefGoogle Scholar
- 28.Matsumoto, H., Shinzaki, S., Narisada, M., Kawamoto, S., Kuwamoto, K., Moriwaki, K., Kanke, F., Satomura, S., Kumada, T., Miyoshi, E.: Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer. Clin. Chem. Lab. Med. 48(4), 505–512 (2010)CrossRefGoogle Scholar